Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples.
暂无分享,去创建一个
C. Huttenhower | L. Waldron | G. Parmigiani | L. Trippa | E. Oliva | M. Birrer | A. Culhane | F. Michor | Sung-Hoon Kim | Wei Wei | Markus Riester
[1] Benjamin Frederick Ganzfried,et al. Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. , 2014, Journal of the National Cancer Institute.
[2] Jinsong Liu,et al. TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. , 2013, Cancer research.
[3] G. Omenn,et al. Evolution of Translational Omics: Lessons Learned and the Path Forward , 2013 .
[4] Benjamin Haibe-Kains,et al. curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome , 2013, Database J. Biol. Databases Curation.
[5] Linlin Tang,et al. The urokinase plasminogen activator system in breast cancer invasion and metastasis. , 2013, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[6] J. Erler,et al. Lysyl oxidase plays a critical role in endothelial cell stimulation to drive tumor angiogenesis. , 2013, Cancer research.
[7] K. Cibulskis,et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. , 2012, The Journal of clinical investigation.
[8] Stephen T. C. Wong,et al. Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. , 2012, Cancer research.
[9] R. Brown,et al. Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review , 2012, British Journal of Cancer.
[10] C. Ricciardelli,et al. Transforming Growth Factor-Beta-Induced Protein (TGFBI)/(βig-H3): A Matrix Protein with Dual Functions in Ovarian Cancer , 2012, International journal of molecular sciences.
[11] Jie Chen,et al. SPARC Is a Key Regulator of Proliferation, Apoptosis and Invasion in Human Ovarian Cancer , 2012, PloS one.
[12] H. Ryu,et al. Impact of Complete Cytoreduction Leaving No Gross Residual Disease Associated with Radical Cytoreductive Surgical Procedures on Survival in Advanced Ovarian Cancer , 2012, Annals of Surgical Oncology.
[13] Beth Y Karlan,et al. Molecular scores to predict ovarian cancer outcomes: a worthy goal, but not ready for prime time. , 2012, Journal of the National Cancer Institute.
[14] Jean-Pierre Gillet,et al. Multidrug Resistance–Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma , 2012, Clinical Cancer Research.
[15] John Quackenbush,et al. Angiogenic mRNA and microRNA Gene Expression Signature Predicts a Novel Subtype of Serous Ovarian Cancer , 2012, PloS one.
[16] R. Carpenter,et al. Hedgehog pathway and GLI1 isoforms in human cancer. , 2012, Discovery medicine.
[17] Tatsuhiko Tsunoda,et al. High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway , 2012, Clinical Cancer Research.
[18] Hong Peng,et al. Interactions between cancer stem cells and their niche govern metastatic colonization , 2011, Nature.
[19] N. Brünner,et al. Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1 , 2011, Expert review of molecular diagnostics.
[20] F. Bertucci,et al. A seven-gene prognostic model for platinum-treated ovarian carcinomas , 2011, British Journal of Cancer.
[21] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[22] M. Pencina,et al. On the C‐statistics for evaluating overall adequacy of risk prediction procedures with censored survival data , 2011, Statistics in medicine.
[23] A. Sood,et al. Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. , 2011, Neoplasia.
[24] B. Karlan,et al. Periostin promotes ovarian cancer angiogenesis and metastasis. , 2010, Gynecologic oncology.
[25] E. Lengyel,et al. Ligand independent activation of c-Met by fibronectin and α5β1-integrin regulates ovarian cancer invasion and metastasis , 2010, Oncogene.
[26] H. Lai,et al. TGF-β: friend or foe? The role of TGF-β/SMAD signaling in epigenetic silencing of ovarian cancer and its implication in epigenetic therapy , 2010, Expert opinion on therapeutic targets.
[27] David M. Simcha,et al. Tackling the widespread and critical impact of batch effects in high-throughput data , 2010, Nature Reviews Genetics.
[28] G. Kenter,et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.
[29] B. Karlan,et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] P. Heikkilä,et al. Metastatic outgrowth encompasses COL-I, FN1, and POSTN up-regulation and assembly to fibrillar networks regulating cell adhesion, migration, and growth. , 2010, The American journal of pathology.
[31] E. Kohn,et al. Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. , 2010, Cancer research.
[32] Ituro Inoue,et al. Gene Expression Profile for Predicting Survival in Advanced-Stage Serous Ovarian Cancer Across Two Independent Datasets , 2010, PloS one.
[33] S. Koscielny. Why Most Gene Expression Signatures of Tumors Have Not Been Useful in the Clinic , 2010, Science Translational Medicine.
[34] W. Wong,et al. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. , 2009, Cancer cell.
[35] K. Coombes,et al. Deriving chemosensitivity from cell lines: Forensic bioinformatics and reproducible research in high-throughput biology , 2009, 1010.1092.
[36] F. Bertucci,et al. Gene expression profiling and prediction of clinical outcome in ovarian cancer. , 2009, Critical reviews in oncology/hematology.
[37] R. Bristow,et al. Predicting the Outcome of Cytoreductive Surgery for Advanced Ovarian Cancer: A Review , 2009, International Journal of Gynecologic Cancer.
[38] W. Weichert,et al. A prognostic gene expression index in ovarian cancer—validation across different independent data sets , 2009, The Journal of pathology.
[39] P. Dijke,et al. Transforming growth factor-beta signaling and tumor angiogenesis. , 2009, Frontiers in bioscience.
[40] H. Hollema,et al. Survival-Related Profile, Pathways, and Transcription Factors in Ovarian Cancer , 2009, PLoS medicine.
[41] J. Erler,et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. , 2009, Cancer cell.
[42] R. Bicknell,et al. Tumor stroma as a target in cancer. , 2008, Current cancer drug targets.
[43] R. Tothill,et al. Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.
[44] Laurent Ozbun,et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. , 2008, Cancer research.
[45] Kevin R Coombes,et al. Run batch effects potentially compromise the usefulness of genomic signatures for ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] K. Dobbin,et al. How Large a Training Set is Needed to Develop a Classifier for Microarray Data? , 2008, Clinical Cancer Research.
[47] Ross S Berkowitz,et al. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] Ying Chen,et al. Functional properties and intracellular signaling of CCN1/Cyr61 , 2007, Journal of cellular biochemistry.
[49] Anil Potti,et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] György Horvath,et al. Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. , 2006, European journal of cancer.
[51] S. Mok,et al. Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. , 2006, Cancer research.
[52] J. Quigley,et al. Matrix metalloproteinases and tumor metastasis , 2006, Cancer and Metastasis Reviews.
[53] Wing H Wong,et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. , 2005, Cancer research.
[54] Wolfgang Viechtbauer,et al. Bias and Efficiency of Meta-Analytic Variance Estimators in the Random-Effects Model , 2005 .
[55] R. Simon,et al. Development and validation of therapeutically relevant multi-gene biomarker classifiers. , 2005, Journal of the National Cancer Institute.
[56] M. West,et al. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. , 2004, American journal of obstetrics and gynecology.
[57] R. Kerbel,et al. Versican/PG‐M G3 domain promotes tumor growth and angiogenesis , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[58] L. Khachigian. Early Growth Response-1: Blocking Angiogenesis by Shooting the Messenger , 2004, Cell cycle.
[59] J. Tukey. Tightening the clinical trial. , 1993, Controlled clinical trials.
[60] C. Perez,et al. Principles and Practice of Gynecologic Oncology , 1992 .
[61] E. DeLong,et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.
[62] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[63] Jack L. Vevea,et al. Fixed- and random-effects models in meta-analysis. , 1998 .
[64] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.